Ben Richardson, CEO at SulNOx, confident they can cost-effectively decarbonise commercial shipping. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
The agreement was from Sept last year so unlikely that they knew the date they would commence given the FDA approval was still pending
An extract from Note 23 of the Financial Statements under Service Agreements:
"In September 2023, Hemogenyx Pharmaceuticals entered into a Master Services and Contract Agreement for a third party to provide clinical services and technologies for the forthcoming Phase I clinical trials for an initial term of 38 months, paying an aggregate of 2,530,057. This includes an upfront payment of 986,713 and monthly instalments over 38 months of 41,712 commencing in April 2024. No sums other than an upfront fee were paid during the year ended 31 December 2023."
- the monthly instalments payments 'commencing April 24' suggests to me that the commencement of the first trial is not that far away now, as Prevail are starting or about to start to undertake the regular work/services to be provided under the contract.
Hope it pays off for you,
Depends what your after I suppose but the slightest sniff of positive news and a sharp rise may provide you with an opportunity to get out with a profit..... or any other option you feel appropriate.
Good luck
Bit the bullet and bought in here this morning. Fingers crossed the gamble pays off
The company featured in this link like to invest in disruptive biotech CBR seems a perfect fit. Worth a call perhaps VS.
https://www.labiotech.eu/podcast/biotech-investment-landscape-2024/
Ssccs....I see you sold HEMO on 4th March 2022.The SP on tha date was 1.22p...I can see why yo are re so bitter...your posting history is gold.
You'd be better posting on stocks you own, not on ones you got shafted on and lost money not crying like a baby and trying to deramp.
Remember,nobody posts on a share they don't own with out a reason...we rtainly don't need your nuggets of shyte.
You'd be much better off channeling your energies towards Vlad rather than a random person in the forum whose posts you don't agree with. Plus I hope you do realise the sp is nothing to do with me?! Crazy person.
I have figured out you are trying your best to deramp this share and my investment you toerag...just do one.
You really haven't figured it out yet have you. Wow.
Why is it dull to post on your only investment???? Filter me if you want, but. Am now studying SYN and it looks really bleak there..10bn shares... crikey..
Hemotruth, I know you find it hard to understand but it doesn't bother me what you post where. Please go for it. Knock yourself out. Live a little. Must be dull to only post on hemo. You are more than welcome at syn.
Yup. It's a public forum, and I have now developed an interest in SYN...enjoy.
You actually posted on syn. You are a total numpty lol.
Just ignore me. Honestly, it's quite easy. I am allowed to post on this board. It's a public board. Filter me... Please
That's a rather large assumption you have made there Hulver. Obviously because it's pro hemo, it's allowed. What a joke this board is. None so blind as those who will not see.
The irony is not lost on me that you talk about emotionally distancing oneself from investment decisions …. yet you are still posting about a share you sold two years ago.
But starting soon ......
HEMO's patients will not be running out of life.
I think there is little doubt that the cash will continue to be raised, when it's needed. The fountain is flowing.
You really need to work on emotionally distancing yourself from your investment decisions
Go for it.. I have already posted the same.
Ssccss the bad smell turns up, not invested but loves to post o a share he sold out on...I wonder why...
SYN looks like a placing coming.. think will post that on your investments
Cash is running out. Do the maths. Vlad needs to find quite a lot of money...
Your last post point is a key one . The directors have prepared accounts on going concern basis and the auditors agree . 12 months from date of signing . The daily doommingers keep telling us cash is running out .
As long as there is sufficient cash and we believe the science is strong ( and frankly the potential looks amazing ) then all we need is patience
Have to agree with this title, and early release suggests Vlad at the LSX conference in London next week (29th/30th) or more news to come, that they wanted to keep separate (if anything worthy of announcement had happened pre-results release then would have to be lost in the PBSE note to the financials?
Going concern - seemingly not too much of an issue to prove for next 12 months (from signing date)
CBR has absolutely unbelievable potential and CAR-T might be the cash cow to allow Hemo to realise some of that potential